Beyond the more-established biomarkers of Aβ, tau, neurodegeneration and neuroinflammation, research has increasingly focused on a diverse array of novel plasma biomarkers that capture additional, critical aspects of AD pathophysiology. This evidence concerns the gene MAPT and Alzheimer disease.